MedTrace Logo

Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

NCT05167864 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2025-01-17

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation. Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 months. All subjects will undergo 3D imaging using the VECTRA M3 (Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order to determine their baseline dimensions. Imaging will be repeated post injection to determine change over time.

Conditions

  • Cosmetic Techniques

Interventions

DRUG

Onabotulinumtoxina for Injection

cosmetic injection into the glabella area (eyebrow area)

DRUG

Abobotulinumtoxina for Injection

cosmetic injection into the glabella area (eyebrow area)

DRUG

IncobotulinumtoxinA for Injection

cosmetic injection into the glabella area (eyebrow area)

DRUG

PrabotulinumtoxinA for Injection

cosmetic injection into the glabella area (eyebrow area)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-04
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05167864 on ClinicalTrials.gov